Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Anne Bregnhøj
Allergic Contact Dermatitis in Children Over a 20-Year Period: A Danish Single-Centre Study
Allergic contact dermatitis (ACD) is a common skin disease caused by delayed-type hypersensitivity to environmental allergens [1]. While previously considered less prevalent in children, ACD is increasingly recognized as an important cause of chronic dermatitis in the paediatric population [2]. Despite growing awareness, long-term longitudinal data on temporal trends in causative allergens remain scarce.
Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa
Key Points Question What is the feasibility of using heat shock protein (HSP) 90 inhibition as a novel mechanism of action in treating hidradenitis suppurativa? Findings In this parallel-design double-blind trial in 15 patients, HSP90 inhibition by oral RGRN-305, 250 mg, once daily resulted in a robust treatment response (n = 10) compared with placebo (n = 5) following 16 weeks of treatment.
Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series
Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series | Dermatology | JAMA Dermatology | JAMA Network [Skip to Navigation] Figure 1. Psoriasis Area and Severity Index (PASI) Scores and Trough Plasma Brodalumab Levels by Weeks of Therapy A, The PASI scores (score range, 0-72, with higher scores indicating severe disease). B, Circulating brodalumab levels in μg/mL (lower limit of quantification is 0.05 μg/mL).
Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial
Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial Autores: Hakim Ben Abdallah, Anne Bregnhøj, Thomas Emmanuel, Gautam Ghatnekar, Claus Johansen, Lars Iversen Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 160, Nº. 1, 2024, págs.
Pustular allergic contact dermatitis caused by sunscreen
CONTACT POINT Eva S. Tracz Corresponding Author E-mail address: eva.tracz@gmail.com https://orcid.org/0000-0002-1185-5747 Department of Dermato‐venereology, Aarhus University Hospital, Denmark Correspondence Eva Susanna Tracz, MD .
Severe bullous allergic contact dermatitis caused by diethylthiourea 20 years after sensitization to neoprene
Contact PointSevere bullous allergic contact dermatitis caused by diethylthiourea 20 years after sensitization to neopreneAuthorsAnne Bregnhøj,Corresponding authorDepartment of Dermato-Venereology, Aarhus University Hospital, 8000 Aarhus C, DenmarkCorrespondence: Anne Bregnhøj, Department of Dermato-Venereology, Aarhus University Hospital, P.P.Ørumsgade 11, 8000 Aarhus C, Denmark. Tel: +45 7846 1861; Fax: +45 7846 1860.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Anne
Contact Anne, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack